DJIA 15,335.28 -19.12 -0.12%
NASDAQ 3,496.43 -2.54 -0.07%
S&P 500 1,666.29 -1.18 -0.07%

AASTROM BIOSCIENCES, INC.

NASDAQ: ASTM

+ Add to Portfolio

company name or ticker

Aastrom Biosciences Management Discusses Q1 2013 Results - Earnings Call Transcript

5/9/2013 by Seeking Alpha

Stem Cells: Invest At Your Own Peril

5/1/2013 by Seeking Alpha

Stocks Hitting 52-Week Lows

4/29/2013 by Benzinga

Investing In The Stem Cell Sector: An Overview

4/17/2013 by Seeking Alpha

Companies That Can Mend The Biotech Market: Stephen Brozak

4/12/2013 by Seeking Alpha

Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel

Aastrom Biosciences Says First Patients Enrolled in ixCELL-DCM Phase 2b Clinical Trial of Ixmyelocel-T
4/4/2013 by Benzinga

Stocks Hitting 52-Week Lows

3/28/2013 by Benzinga

Benzinga's Top Downgrades

3/28/2013 by Benzinga

Market Close: Big Winners & Losers for March 27, 2013 (CHCI, RDHL, UEPS, RVLT, LIVE, ASTM, EVBS, ISN

Market Close: Big Winners & Losers for March 27, 2013 (CHCI, RDHL, UEPS, RVLT, LIVE, ASTM, EVBS, ISNS, ATOS, GV)
3/27/2013 by 247wallst

Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE

Oppenheimer Reiterates Perform Rating on Aastrom Biosciences on Discontinuation of Phase III REVIVE CLI
3/27/2013 by Benzinga
See More Articles...